| 000 | 01605 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515043303.0 | ||
| 264 | 0 | _c20061128 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a0300-9475 | ||
| 024 | 7 |
_a10.1111/j.1365-3083.2006.01843.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSathler-Avelar, R | |
| 245 | 0 | 0 |
_aBenznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. _h[electronic resource] |
| 260 |
_bScandinavian journal of immunology _cNov 2006 |
||
| 300 |
_a554-63 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 |
_aChagas Disease _ximmunology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aCytokines _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunity, Innate |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNitroimidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aTrypanosoma cruzi _ximmunology |
| 700 | 1 | _aVitelli-Avelar, D M | |
| 700 | 1 | _aMassara, R L | |
| 700 | 1 | _aBorges, J D | |
| 700 | 1 | _aLana, M | |
| 700 | 1 | _aTeixeira-Carvalho, A | |
| 700 | 1 | _aDias, J C P | |
| 700 | 1 | _aElói-Santos, S M | |
| 700 | 1 | _aMartins-Filho, O A | |
| 773 | 0 |
_tScandinavian journal of immunology _gvol. 64 _gno. 5 _gp. 554-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-3083.2006.01843.x _zAvailable from publisher's website |
| 999 |
_c16608765 _d16608765 |
||